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Abstract
Background: The occurrence of Parkinson’s disease (PD) is known to be associated both with increased nigrostriatal iron
content and with low serum cholesterol and PD, but there has been no study to determine a potential relationship between
these two factors.
Methods: High-resolution MRI (T1-, T2, and multiple echo T2*-weighted imaging) and fasting lipid levels were obtained
from 40 patients with PD and 29 healthy controls. Iron content was estimated from mean R2* values (R2*=1/T2*) calculated
for each nigrostriatal structure including substantia nigra, caudate, putamen, and globus pallidus. This was correlated with
serum cholesterol levels after controlling for age, gender, and statin use.
Results: In patients with PD, higher serum cholesterol levels were associated with lower iron content in the substantia nigra
(R=20.43, p=0.011 for total-cholesterol, R=20.31, p=0.080 for low-density lipoprotein) and globus pallidus (R=20.38,
p=0.028 for total-cholesterol, R=20.27, p=0.127 for low-density lipoprotein), but only a trend toward significant
association of higher total-cholesterol with lower iron content in the striatum (R=20.34, p=0.052 for caudate; R=20.32,
p=0.061 for putamen). After adjusting for clinical measures, the cholesterol-iron relationships held or became even stronger
in the substantia nigra and globus pallidus, but weaker in the caudate and putamen. There was no significant association
between serum cholesterol levels and nigrostriatal iron content for controls.
Conclusions: The data show that higher serum total-cholesterol concentration is associated with lower iron content in
substantia nigra and globus pallidus in Parkinson’s disease patients. Further studies should investigate whether this is
mechanistic or epiphenomenological relationship.
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Introduction
Although the etiology is known in a small percentage of
genetically-linked cases, Parkinson’s disease (PD) is largely
idiopathic, and likely involves interaction of host susceptibility
(determined by our genome and/or behavior) and environmental
factors. Besides the well documented loss of dopamine neurons in
the substantia nigra (SN) [1], increased iron content in the SN also
has been found postmortem in PD [2–4]. Ferritin-bound iron is
paramagnetic, and causes a strong reduction in the proton
transverse relaxation time (T2*) [5]. Several brain MRI studies
have shown that the proton transverse relaxation rate (R2*=1/
T2*) is correlated with iron concentration in brain tissue [6,7], and
is increased in SN of PD patients [6,8–12]. The exact role of this
iron accumulation in PD is, however, unclear.
It is known that genetic alterations of some proteins involved in
the regulation of iron homeostasis can cause brain iron
accumulation and neurodegenerative disorders in humans
[13,14]. These disorders, grouped under the name ‘‘neurodegen-
eration with brain iron accumulation’’, [15] include pathothenate
kinase-associated neurodegeneration (PKAN) [16], hereditary
aceruloplasminemia [17], and neuroferritinopathy [18]. In
addition, iron regulatory protein-2 null mice that have alterations
in brain iron homeostasis show neurodegeneration and develop
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hypothesis that iron dysregulation may have an etiological role in
neurodegenerative diseases.
Excessive accumulation of iron in neurons causes toxicity
presumed to result from alterations in the ratio of ferric to ferrous
iron and subsequent production of toxic hydroxyl radicals [20,21].
Furthermore, iron deposition in the brain can promote confor-
mational changes in a-synuclein, resulting in aggregation and
possible contribution to the pathogenesis of PD [22]. Thus, it may
be that iron deposition contributes to brain damage in patients
with PD [20,23,24]. It also is known that iron binding capacity
may be increased with higher metabolism [25]. Furthermore,
catecholamine synthesis and degradation requires iron as a co-
factor [26] and thus the increased iron in the SN may reflect this
increased synthesis. Thus, it also is possible that increased iron
content may represent a compensatory change due to primary
pathology. Little is known, however, about the factors associated
with increased iron accumulation in the SN of PD patients.
Recent studies also suggest higher serum cholesterol may be
related to a lower occurrence [27–32] and slower progression [33]
of PD, although one prospective study offered a contradictory
finding [34]. The weight of the evidence clearly favors an inverse
association between serum cholesterol and occurrence of PD.
Whether serum cholesterol and iron deposition are related in PD,
however, is unknown. One study found lower dietary cholesterol
intake, particularly with higher iron intake, correlated with an
increased risk for PD, suggesting cholesterol and iron may be part
of a chain of events leading to the death of dopaminergic neurons
[35]. For these reasons, we tested the hypothesis that higher serum
cholesterol levels are associated with lower iron accumulation in
the SN and related down stream nigrostriatal structures in PD.
Methods
Subjects
Forty PD subjects and 29 controls were recruited from patients,
their spouses, and relatives presenting to a tertiary movement
disorders clinic (see Table 1 for detailed demographic informa-
tion). PD diagnosis was confirmed by a movement disorder
specialist (XH) according to published criteria [36]. Unified PD
Rating Scale part III (UPDRS-III) motor scores were obtained for
each PD subject after withholding all PD medication overnight
(,12 h). The levodopa equivalent dose (LEDD) was estimated for
PD subjects according to a published formula [37]. All subjects
gave written informed consent that was consistent with the
Declaration of Helsinki, and this study was reviewed and approved
by the Penn State Hershey Institutional Review Board.
Determination of fasting serum total and low density
lipoprotein (LDL)-cholesterol levels
Four milliliter blood specimens were obtained from all subjects
after overnight fasting. The blood samples were allowed to clot for
30 min and then centrifuged within one hour after collection until
clot and serum were clearly separated. The serum then was
transferred into a plastic vial and serum lipids were measured by
standard biochemical methods as described in the Vitros
Chemistry product manual (Ortho-Clinical Diagnostics, Inc.,
Rochester, NY) at the Penn State Milton S. Hershey Medical
Center Clinical Laboratory.
MRI Data acquisition
All subjects were scanned using a 3.0 tesla MR Scanner (Trio,
Siemens Magnetom, Erlangen, Germany, with an 8-channel
phased array head coil) and high-resolution T1- and T2-weighted
images, along with T2*-weighted (multiple gradient echoes)
images, were collected. A magnetization-prepared rapid acquisi-
tion gradient echo sequence was used to obtain T1-weighted
images with TR=1540 ms, TE=2.34 ms, field of
view=256 mm, matrix=2566256, slice thickness=1 mm (with
no gap), slice number=176. T2-weighted images were collected
using a fast-spin-echo sequence with TR=2500, TE=316, with
the same resolution configuration as that for T1-weighted images.
A multiple gradient echoes sequence was used to estimate the
proton transverse relaxation rate, R2* (R2*=1/T2*) [38]. Six
echoes with TEs ranging from 7 to 47 ms and an interval of 8 ms
were acquired with TR=54 ms, flip angle=20u, field of
view=256 mm, matrix=2566256, slice thickness=1 mm (with
no gap), slice number=64.
Image processing and analysis
Segmentation of regions of interest (ROIs). The SN was
delineated manually. Individual high resolution T2-weighted
images were reformatted by positioning the AC-PC line to the
center of the image and then rotating the AC-PC line 35u superior
to the PC point and along the mid-sagittal plane, as shown in
Figure 1A. The 35u rotation was used to minimize the inclusion of
the subthalamic nucleus that lays superior-anterolateral to the SN
[39,40]. The SN was defined as a hypo-intensity band between the
red nucleus and cerebral peduncle in axial sections on the
multiplanar reformatted T2-weighted images. The segmentation
of the SN was started at one slice lower than the level of the red
nucleus showing the largest radius. A total of five slices (from the
dorsal to ventral parts of the SN, 5 mm height) were used as the
ROI of the SN. The level of the SN is shown as the yellow band in
Figure 1A. ITK-SNAP (www.itksnap.org) was used to perform
manual segmentation, whereas an in-house multi-plane reforma-
tion tool was used to reformat T2-weighted images and then
transform the ROIs from the reformatted coordinate space to the
original coordinate space for further analysis [41]. The reasons the
SN is treated as one ROI instead of separating it into the pars
compacta and pars reticulata subregions are 1) the exact
demarcation of the pars compacta and pars reticulata on T2-
weighted images still remains controversial according to recent
studies [6,42–45]; and 2) the distribution of dopaminergic neurons
within the substantia nigra is quite heterogeneous and possibly
spreads into the pars reticulata. [46,47]. The putamen, caudate,
and global pallidus (GP) were segmented by using a probabilistic
atlas-based automatic segmentation software AutoSeg (Neuro
Image Research and Analysis Laboratories, University of North
Carolina at Chapel Hill, NC, USA) on T1-weighted and T2-
weighted images [48,49]. The segmentation results are illustrated
in Figures 1B and 1C.
R2* maps. The multiple gradient echoes images were used to
estimate the R2* maps by using a voxel-wise linear least-squares fit
to a mono-exponential function with free baseline using an in-
house MATLAB (The MathWorks, Inc., Natick, MA) tool. An
affine registration process implemented in 3D Slicer (www.slicer.
org) then was used to map ROIs to the R2* maps and reduce
motions artifacts between T2-weighted and multiple gradient
echoes T2* images by co-registering T2-weighted images to an
averaged magnitude image of the six echoes. For each individual
subject, the mean R2* values of the SN were calculated by using
the trimmed mean (from the 5%–95% percentile) of all voxels in
the ROI to reduce variability introduced by potential segmenta-
tion and/or registration errors. We used trimmed means because
they represent a more robust central estimator of the measure-
ment, and they are based on the assumption that the top and
bottom 5% values represent potential errors.
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The demographic data of PD subjects and controls were
compared using two-sample t-tests and Fisher’s exact tests as
appropriate. Regional R2
* values and serum cholesterol levels
were compared separately between PD and controls by analyses of
covariance with adjustments for age, gender, and the use of
cholesterol lowering drugs (statins). The correlations between R2*
values and serum cholesterol levels in PD and control subjects
were determined using Spearman’s partial correlation coefficients
(robust to departures from normality, including the presence of
outliers), with adjustment for the effects of age, gender, and statin
use in both PD and controls separately. The relationship between
UPDRS-III scores, disease duration, LEDD, and both R2* values
and serum cholesterol levels were explored by Spearman’s partial
correlation analysis in the PD group. The statistics are presented
without a multi-comparison correction because the explored
variables are intrinsically dependent and the exploratory nature
of this study. All statistical analyses were performed using SAS 9.2
(SAS Institute Inc., Cary, NC, USA).
Results
As shown in Table 1, there were no significant differences
between PD and controls in terms of age, gender, or statin use
Table 1. Overall characteristics of study subjects.
Parkinson’s disease Controls p-value
Demographics
No. (female, male) 40 (17, 23) 29 (17, 12) 0.227
a
Age, years (mean6SD, y) 60.768.3 59.666.7 0.551
b
UPDRS-III motor scores (mean6SD) 23.4615.2 - N/A
Disease duration, years (mean6SD, y)
d 4.264.7 - N/A
Hoehn and Yahr Stage (I/II/III) 14/22/4 - N/A
Levodopa equivalent dose (LEDD, mg) 5326395 - N/A
Statin use (yes/no) 9/31 6/23 1.000
Serum fasting cholesterol levels
Total-cholesterol (mean6SD, mg/dL) 195636 201639 0.852
c
LDL-cholesterol (mean6SD, mg/dL) 123629 121634 0.607
c
R2* values in nigrostriatal pathways
SN 34.965.7 30.464.6 0.001
c
Caudate 22.363.5 22.462.6 0.720
c
Putamen 28.464.7 27.363.1 0.394
c
GP 37.266.0 35.664.2 0.117
c
ap-value is calculated from Fisher’s exact test.
bp-value is calculated from two-sample Student’s t-test with equivalent variance.
cp-value is calculated from ANCOVA with adjustment for age, gender, and use of statins.
dDisease duration is defined as the years since diagnosis.
doi:10.1371/journal.pone.0035397.t001
Figure 1. The segmentation procedure for the substantia nigra and nigrostriatal structures. An illustration of reformatting position used
for the segmentation of the substantia nigra (1A) and the segmentation example of the nigrostriatal structures (1B and 1C).
doi:10.1371/journal.pone.0035397.g001
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higher compared to that of controls. There were no significant
differences between PD and controls in either total-cholesterol or
LDL-cholesterol measurements. As shown in Table 2 (and Figure
S2), the R2* values in the SN were associated with all three clinical
measurements [i.e., UPDRS-III, disease duration, and LEDD].
UPDRS-III motor scores were negatively correlated with serum
cholesterol levels in PD subjects, but only reached statistical
significance with LDL-cholesterol levels (R=20.397, p=0.020)
and not total-cholesterol (R=20.334, p=0.054). Neither of the
serum cholesterol levels was correlated with the other two clinical
measurements.
When regression analyses between serum cholesterol and iron
measurements were performed, there were two outliers (one in
each group) detected with regard to serum cholesterol levels
(shown in Figure S1). Each of these subjects had extremely high
cholesterol levels despite the fact that both subjects were taking
cholesterol-lowering drugs. The serum cholesterol level was
290 mg/dL (196 mg/dL LDL-cholesterol) for the PD subject
and 285 mg/dL (204 mg/dL LDL-cholesterol) for the control,
with all values greater than two times the standard deviation of the
overall groups. Because these extreme outliers may bias the
correlations analysis, the remaining results come from 39 PD
subjects and 28 controls with the two outliers excluded. The
correlation analysis results (including those two outliers) are
presented in the supplementary material (see Table S1 and Figure
S1).
As seen in Table 3 and Figure 2, after controlling for age,
gender, and statin use, higher serum cholesterol levels were
associated with lower iron content in the SN of PD subjects. The
association reached statistical significance with total-cholesterol
level (R=20.43, p=0.011), but not for LDL-cholesterol level
(R=20.30, p=0.080). Higher serum cholesterol levels also were
correlated with lower iron content in the GP in PD subjects. The
association reached statistical significance with total-cholesterol
level (R=20.38, p=0.028), but not with LDL-cholesterol level
(R=20.27, p=0.127). The relationship between total-cholesterol
and iron content in the SN of PD subjects remained after adjusting
either individually (data not shown) or collectively for the three
clinical scores (UPDRS-III motor scores, duration of illness, and
LEDD). The association between both cholesterol levels and iron
content in the GP was even stronger after adjusting for clinical
scores (see Table 3 and Figure S2).
There was a trend for an association between total-cholesterol
and iron content in the striatum (R=20.34, p=0.052 for
caudate; R=20.32, p=0.062 for putamen) in the PD group,
but the trend was weakened after adjusting for clinical scores. The
association between LDL-cholesterol level and iron content in PD
subjects was not significant in striatal structures, and similar to
total-cholesterol, the relationship was further weakened after
adjusting for clinical scores (see Table 3). In controls, serum total-
cholesterol was not significantly associated with iron content in the
SN (R=0.16, p=0.46), striatum (R=20.34, p=0.11 for caudate;
R=20.36, p=0.091 for putamen), or GP (R=20.063, p=0.78),
nor was LDL-cholesterol level correlated with iron content in any
nigrostriatal structure (see Table 3).
Discussion
The current study was designed to be a first test of the
hypothesis that iron contents in SN and serum cholesterol levels
were associated in PD. This study provides the first evidence that
higher serum cholesterol in PD patients may be associated with
lower iron content in the SN and GP. This relationship is not
present in age- and gender-matched controls, suggesting that this
is a PD- or neurodegeneration-specific association. The data
therefore support future efforts to test the hypothesis that
cholesterol and iron may be interwoven into a chain of events
that relates either to the death of dopamine neurons, and/or
compensatory changes in PD. On the other hand, these data
cannot rule out the null hypothesis that they are two unrelated
changes that occur in PD (see Introduction). The mechanism and
implication of the cholesterol-iron association at iron enriched
brain structures in PD need to be explored further, and may shed
light on understanding the pathoetiology or physiology of PD and
related disorders.
Consistent with previous reports [6,8–12], PD subjects demon-
strated a significant increase in the R2* value in the SN compared
to controls in the present study. In addition, we found a significant
correlation between the SN R2* value and all three clinical scores
in PD. This is consistent with the idea that R2* in the SN may
have utility as an imaging marker for PD progression. Unlike the
previous study [6], and considering the exploratory aspect of the
present work and controversies surrounding the definition of the
subregions of the SN [6,42,43,45], we separated neither the two
subregions of the substantia nigra, nor the more- and less-affected
sides. Consequently, one limitation of our study is that we could
not explore the relationship between R2* and clinical measure-
ments in a more detailed way as was done in these previous studies
[6]. The PD group in the present work has a slightly broader
Table 2. Spearman’s partial correlation coefficients and p-value (in parentheses) between clinical scores and R2* values or serum
cholesterol levels.
Clinical measurements
UPDRS-III motor scores Disease Duration LEDD
Lipid profiles Total-cholesterol 20.334 (0.054) 20.175 (0.322) 20.052 (0.768)
LDL-cholesterol 20.397 (0.020) 20.062 (0.727) 0.040 (0.824)
R2* in brain regions SN 0.355 (0.039) 0.418 (0.014) 0.407 (0.017)
Caudate 0.397 (0.020) 0.055 (0.758) 0.266 (0.128)
Putamen 0.431 (0.011) 0.144 (0.417) 0.424 (0.012)
GP 20.142 (0.424) 20.061 (0.732) 0.130 (0.464)
Bold-italicized numbers are statistically significant results with p,0.05 (p value in parentheses).
UPDRS-III represents Unified Parkinson’s Disease Rating Scale-Motor part;
LEDD represents levodopa equivalent dosage.
doi:10.1371/journal.pone.0035397.t002
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that may explain why we were able to find a stronger correlation
between R2* values and the clinical measurements. Nevertheless,
similar to the previous studies, the PD subjects in the current study
are relatively early in their disease course. Additional researches
with larger sample sizes that include more advanced stage disease
patients are warranted to test this hypothesis more rigorously.
Two previous case-control studies reported significantly lower
cholesterol in PD than in controls, each study involving more than
100 PD and 100 controls [28,50]. The current study of 40 PD and
29 controls is clearly underpowered to detect any significant group
difference between PD and control groups for these measure-
ments, and also had gender ratios that were different between PD
and control groups. Despite this lack of significant group
differences, mean total-cholesterol level, LDL-cholesterol level,
and their standard deviations in the current study, however, are
very similar to what we reported previously [27], where 124 PD
and 112 control subjects were studied. In this previous study [27],
higher cholesterol level quartiles were associated with lower
prevalence of PD, although the sample size for the current study
was too small for a similar analysis. Also like the current study,
Huang et al. [27] did not find an association between cholesterol
levels and duration of illness. The current data does suggest that in
the PD group, higher cholesterol levels seemed to be associated
with better UPDRS-III motor scores, consistent with the recent
report of Ikeda et al. [50]. It is possible that severe clinical disease
is marked by higher iron content in the SN, resulting in changes in
cholesterol profiles through malnutrition or behavioral changes. In
our study, however, after further adjusting for clinical scores (the
UPDRS-III motor scores, disease duration, and LEDD), the
relationship between cholesterol levels and iron in both the SN
and GP in PD subjects remained (in SN) or became even stronger
(in GP). These result are not consistent with the notion that
disease-induced motor change or drug use are the primary cause
of the cholesterol-iron link in PD, but future studies with parallel
assessments of nutritional status are needed to address this
question directly.
Although there was no overall difference in iron accumulation
in the GP between PD and controls, higher cholesterol in PD was
associated with lower iron content in this structure. This
association is also PD-specific and not observed in controls.
Whereas the GP, like the SN, is known to be a ‘‘sink’’ for metals
(e.g., Fe, Mn, Cu) [51–54] and is lack in transferrin-binding sites
[55], it does not contain dopamine neurons, but it is vulnerable to
iron-mediated (e.g., Hallervorden Spatz disease, PKAN and
oxidative stress-related neuronal and glial damage such as that
observed due to carbon monoxide toxicity [20]. This implies that
the cholesterol-iron association in PD is most likely specific to iron-
rich and oxidative stress-vulnerable structures, but is not
necessarily dopamine neuron-mediated. The exact reasons for
Table 3. Spearman’s partial correlation coefficients and p-values (in parentheses) between regional R2* and serum cholesterol
levels in PD and Controls.
Controls Parkinson’s disease
(adjusted for age, gender, and statin use) (adjusted for age, gender, and statin use)
(adjusted for age, gender , statin use, and
clinical scores*)
Total-cholesterol LDL-cholesterol Total-cholesterol LDL-cholesterol Total-Cholesterol LDL-cholesterol
SN 0.163 (0.458) 0.213 (0.329) 20.429 (0.011) 20.305 (0.080) 20.391 (0.030) 20.287 (0.118)
Caudate 20.339 (0.114) 20.226 (0.299) 20.336 (0.052) 20.279 (0.110) 20.307 (0.093) 20.209 (0.260)
Putamen 20.360 (0.091) 20.243 (0.264) 20.324 (0.062) 20.232 (0.188) 20.329 (0.071) 20.199 (0.283)
GP 20.063 (0.775) 20.116 (0.599) 20.376 (0.028) 20.267 (0.127) 20.552 (0.001) 20.477 (0.007)
Bold-italicized numbers are statistically significant results with p,0.05 (p value in parentheses).
*Clinical scores include UPDRS-III motor scores, disease duration, and LEDD.
doi:10.1371/journal.pone.0035397.t003
Figure 2. Correlation between nigrostriatal iron and serum
cholesterol levels. Partial residual plots of nigrostriatal iron deposi-
tion and serum cholesterol levels in Parkinson’s disease subjects. X-axes
are serum cholesterol levels; y-axes are R2* values controlling for age,
gender, and statin use. R and p-values are from Spearman’s partial
correlation analysis.
doi:10.1371/journal.pone.0035397.g002
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exploration.
The current study has several limitations. First, although our
sample size of 40 patients and 29 controls is substantial compared
to some other PD neuroimaging studies, it is a relatively small
sample size for a cross-sectional study. Second, of those subjects
participating in the study, nine PD patients and six controls used
statins. Statin use may affect these data in complicated ways
because these drugs not only modify cholesterol levels, but also
have been hypothesized to have anti-neurodegenerative properties
[56,57]. In the current study, the potential effects caused by statins
were adjusted by using partial correlation analysis with statin use
as a covariate. We did not exclude subjects taking statins from the
analyses due to sample size concerns and also because such
exclusion would have differentially excluded subjects with higher
cholesterol levels. We did, however, obtain the historical, pre-
statin fasting total- and LDL-cholesterol levels from the medical
records of statin users. The association between cholesterol levels
and iron content in nigrostriatal structures was essentially
unaffected by this (data not shown). Although the current data
are consistent with the hypothesis that lower cholesterol may
contribute to brain iron accumulation and later neurodegenera-
tion, other possibilities exist that should be addressed in future
studies.
In summary, this study is the first relating serum cholesterol
levels and iron content in nigrostriatal structures in PD. Future
studies, preferably prospectively following a large group of PD
patients with a statistical analysis strategy that corrects for multiple
comparison and a, feasible strategy for separating the SN into the
pars compacta and pars reticulata, clearly are warranted, and may
shed light on understanding the pathoetiology and/or physiology
of PD and related disorders.
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Figure S1 Partial residual plots of nigrostriatal iron
deposition and serum total-cholesterol levels with the
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